Beyond omnichannel: Why pharma commercialisation must shift to omnideployment

The pharmaceutical industry has a deep-seated love affair with omnichannel. It is the word of the decade, dominating slides, agency pitches, and executive roundtables. Yet, if you sit down with five different commercial leaders and ask them what omnichannel actually means in practice, you will get five vastly different, often vague, answers. For too many teams, it has simply become a corporate euphemism for doing more of the same: sending more automated emails, launching more banner ads, and hoping something eventually lands.

But as therapies become more targeted and patient pathways grow increasingly complex, simply being present on multiple channels is no longer a viable strategy. In fact, the traditional omnichannel rush has often created the opposite of its intended effect: a fragmented mess of disconnected tactics, overlapping vendors, and a constant drone of digital noise that alienates healthcare professionals (HCPs), rather than supporting them.

We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.

Omnideployment is not about multiplying touchpoints or increasing the volume of communications. It is the precise coordination of intelligence, high-value content, and face-to-face human interaction to change clinical behaviour and ensure that the right patients receive the right care.

Moving the goalposts from clicks to conversations

In traditional digital marketing, we are addicted to vanity metrics. We measure success by impressions, open rates, page views, and clicks because they are easy to put on a dashboard. But does a high click-through rate on an email actually mean an HCP has gained the confidence to prescribe a complex new therapy? Does a page view solve a diagnostic bottleneck? Rarely.

Omnideployment changes the focus entirely. Here, the ultimate metric is whether we are equipping our field representatives, medical science liaisons (MSLs), and key opinion leaders (KOLs) to advance a meaningful clinical conversation.

Every digital asset, educational resource, and live interaction must serve this single, cohesive purpose. Rather than publishing content and hoping for the best, content must be deployed with an explicit, behavioural goal in mind. In this setup, predictive tools and data analysis do not exist to auto-generate spam. Instead, they serve as the operational backbone, turning raw, multi-channel data into immediate, practical advice for the people on the front lines.

Trading launch speed for launch intelligence

The standard pharmaceutical commercial playbook has always prioritised speed. "First to market" and "fastest to peak sales" are treated as the golden standards. But speed without precision is just expensive waste.

We have to redefine speed to market as the intelligent delivery of long-term brand value. A smarter launch strategy is built on a deep, continuous understanding of the entire clinical ecosystem.

This ecosystem has to operate as a single, connected organism, rather than a collection of siloed vendors. When predictive intelligence is placed at the center, the commercial model can constantly digest market signals and adapt in real time. This ensures that the launch strategy responds to local physician needs and actual patient pathway challenges, directing resources exactly where they will make a tangible difference.

Integrating the DNA of digital and field teams

One of the most persistent operational failures in modern pharma is the artificial barrier built between digital marketing and field sales. They are treated as separate worlds, managed by different teams, funded by separate budgets, and measured by conflicting KPIs.

But digital and field interactions are not distinct disciplines; they are two sides of the exact same strategic coin. A field representative or MSL sitting down with an HCP is the human interface of your digital strategy.

When you fully integrate these two forces, the customer experience becomes a continuous loop. A field representative can share a short, highly relevant clinical video with an HCP ahead of a scheduled meeting. During the face-to-face discussion, they can walk through an approved interactive visual tool, subsequently enrolling the HCP in a continuous medical education programme, and follow up with digital materials that directly address the specific clinical questions raised during the meeting.

Reimagining content as a behavioural engine

If we want to change clinical behaviour, we have to look at content differently. Content is the vehicle through which we transform scientific evidence into physician confidence, confidence into clinical conversation, and conversation into better patient care.

However, producing high-quality, compliant scientific content is incredibly expensive and time-consuming. To make an omnideployment model work at scale, we must stop creating one-off assets and instead adopt a modular, reusable content strategy.

At the top of this strategy is high-impact video. Consider a single, in-depth, 30-minute discussion between two trusted clinical experts. Instead of treating this as a single asset to be posted on a portal and forgotten, it should be treated as the raw material for an entire campaign. We can carve out short, highly focused video clips for social feeds or doctor portals, build bite-sized podcasts for commutes, and construct representative-triggered follow-up emails.

This modular approach ensures that the most relevant clinical arguments are tailored directly to the specific physicians who need them, without requiring creative teams to start from scratch every single time.

From isolated tactics to real accountability

Ultimately, commercial leaders must stop accepting fragmented deliverables and begin demanding connected, accountable operating systems.

A successful strategy requires a single, unbroken thread that runs all the way from clinical development through product launch, localisation, medical education, field execution, and patient support. It requires shared goals, integrated content, and unified feedback loops.

If our work does not actively connect HCP education to field actions, field actions to content optimisation, and content optimisation to actual improvements in the patient journey, then we do not have a strategy – we just have a collection of expensive tactics.

Omnideployment is simply digital communication with a clear, clinical destination. It is field deployment backed by an adaptive learning system. It is content written with a clear behavioural purpose. By making this transition, we move past the noise of modern marketing toward what actually matters: more informed physicians, smarter clinical discussions, faster patient identification, and better access to life-changing treatments.

About the author

James May is the global media lead at EVERSANA INTOUCH, where he oversees the strategic design and delivery of integrated, global media programmes for the life sciences sector. With extensive expertise spanning digital marketing, media strategy, and field force engagement, May focuses on shifting the industry from passive omnichannel tactics to active, accountable omnideployment. He specialises in leveraging predictive intelligence and modular content to connect scientific evidence with healthcare provider behaviour. Based in the UK, May is committed to helping pharmaceutical organisations achieve launch intelligence, optimise clinical conversations, and ultimately deliver life-changing treatments to patients worldwide.